Skip to content

Novavax NVAX Cash ratio

Cash ratio at other companies

Moderna logo
ModernaMRNA
0.8×-0.2×
Roivant Sciences logo
Roivant SciencesROIV
+4.4×
Merck & Co. logo
Merck & Co.MRK
0.2×-0.1×
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
1.1×-2.5×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.4×0.0×
ALN
Alnylam PharmaceuticalsALNY
1.3×+0.3×

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Calculated from Novavax’s reported figures.

Based on the most recent quarter.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's cash ratio?
Novavax (NVAX) reported cash ratio of 0.7× in Q1 2026.
How has Novavax's cash ratio changed year-over-year?
Novavax's cash ratio increased by 6.9% year-over-year, from 0.6× to 0.7×.
What is the long-term trend for Novavax's cash ratio?
Over 5 years (2020 to 2025), Novavax's cash ratio has grown at a -11.3% compound annual growth rate (CAGR), from 1× to 0.5×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.